LAG3 PET Imaging in Advanced Solid Tumors
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04706715|
Recruitment Status : Recruiting
First Posted : January 13, 2021
Last Update Posted : February 15, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Metastatic Solid Tumor||Other: 89Zr-DFO-REGN3767 Drug: Cemiplimab||Phase 1 Phase 2|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||38 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||ImmunoPET Imaging With 89Zr-DFO-REGN3767 in Patients With Advanced Solid Cancer Prior to and During Treatment With Cemiplimab With or Without Platinum-based Chemotherapy|
|Actual Study Start Date :||January 18, 2022|
|Estimated Primary Completion Date :||September 2024|
|Estimated Study Completion Date :||September 2024|
Experimental: Dose finding cohort
In part A of this imaging trial, a dose finding study will be performed to establish safety, to assess the appropriate protein dose for PET-scanning and to assess the appropriate PET scanning interval. After completion of imaging, patients will start treatment with cemiplimab with or without platinum-based chemotherapy.
Anti-LAG-3 PET imaging tracer
Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
Experimental: Feasibility cohort
The purpose of part B of the study is to analyze the PK of 89Zr-DFO-REGN3767 in patients before and during treatment with cemiplimab with or without platinum-based chemotherapy.
Anti-LAG-3 PET imaging tracer
Cemiplimab 350 mg every 3 weeks with or without platinum-based chemotherapy.
- Optimal 89Zr-DFO-REGN3767 dose and PET imaging timepoint [ Time Frame: 2 years ]Determine the optimal 89Zr-DFO-REGN3767 dose and optimal PET imaging timepoint.
- Pharmacokinetics (PK) of 89Zr-DFO-REGN3767 [ Time Frame: 2 years ]Description of PK of 89Zr-DFO-REGN3767 by measuring standardized uptake value (SUV) on PET scans performed 0, 2, 4 and/or 7 days after tracer injection.
- Incidence of adverse events related to 89Zr-DFO-REGN3767 administration as assessed by CTCAE v5.0 [ Time Frame: 2 years ]Safety assessment through summaries of adverse events, changes in laboratory test results (if evaluation is indicated) and changes in vital signs. Adverse event data will be recorded and summarized according to NCI CTCAE v5.0
- Heterogeneity of 89Zr-DFO-REGN3767 antibody tumor uptake [ Time Frame: 2 years ]Heterogeneity of 89Zr-DFO-REGN3767 uptake will be evaluated by measuring standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images.
- Correlation of tumor tracer uptake with tumor and immune cell LAG3 expression [ Time Frame: 2 years ]Results of immunohistochemical (IHC) scoring of immune cell LAG3 expression will be described as a semi-quantitative score using the percentage of positive cells (continuous variable), intensity and pattern of staining (discrete variable). These IHC results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images.
- Correlation of tumor tracer uptake with response to cemiplimab [ Time Frame: 2 years ]Response to therapy with cemiplimab (with or without chemotherapy) will be assessed according to the RECIST or iRECIST guidelines. These results will be compared with imaging tracer standardized uptake value (SUV) in defined volumes of interest (VOIs) of tumor lesions on the PET scan images.
- Assessment of changes in tumor and normal organ uptake [ Time Frame: 2 years ]Patients enrolled in part B will undergo a PET scan at baseline and another one after 2 treatment cycles. 89Zr-DFO-REGN3767 tracer uptake will be quantified and expressed as standardized uptake value (SUV) in defined volumes of interest (VOIs) for both scans. The results of both PET scans will be compared to assess changes in imaging tracer uptake over time.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Age ≥ 18 years at the time of signing informed consent.
- Patients with histologically confirmed diagnosis of locally advanced or metastatic solid cancer types who, according to the opinion of the investigator, based on available clinical data, may benefit from PD1 antibody with or without platinum-based chemotherapy.
- At least 1 lesion that is accessible per investigator's assessment and eligible for biopsy according to standard clinical care procedures.
- Measurable disease, as defined by standard RECIST v1.1. Previously irradiated lesions should not be counted as target lesions except for lesions that have progressed after radiotherapy.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy ≥ 12 weeks.
Adequate organ and bone marrow function as defined below:
- Hemoglobin ≥9.0 g/dL
- Absolute neutrophil count ≥1.5 x 109/L
- Absolute lymphocyte count ≥0.75 x 109/L
- Platelet count ≥100 x 109/L
- Serum creatinine ≤1.5 x upper limit of normal (ULN) or estimated glomerular filtration rate > 30 mL/min/1.73 m2. A 24-hour urine creatinine collection may substitute for the calculated creatinine clearance to meet eligibility criteria.
- Adequate hepatic function:
i. Total bilirubin ≤1.5 x ULN (≤3 x ULN if liver tumor involvement); Patients with Gilbert's syndrome do not need to meet total bilirubin requirements, provided their total bilirubin is unchanged from their baseline. Gilbert's syndrome must be documented appropriately as past medical history.
ii. Aspartate aminotransferase (AST) ≤2.5 x ULN (≤5 x ULN if liver tumor involvement) iii. Alanine aminotransferase (ALT) ≤2.5 x ULN (≤5 x ULN if liver tumor involvement) iv. Alkaline phosphatase (ALP) ≤2.5 x ULN (≤5 x ULN if liver or bone tumor involvement)
- Signed informed consent.
- Willingness and ability to comply with all protocol required procedures.
- Treatment with any approved anti-cancer therapy, investigational agent, or participation in another clinical trial with therapeutic intent within 28 days prior to 89Zr-DFO-REGN3767 injection.
- Prior ICI treatment, including but not limited to anti-PD1 and anti-PD-L1 therapeutic antibodies.
- Encephalitis, meningitis or uncontrolled seizures in the year prior to inclusion.
- Any unresolved toxicity (>CTCAE grade 2) from previous anti-cancer therapy. Subjects with irreversible toxicity that is not reasonably expected to be exacerbated by the investigational product may be included (e.g., hearing loss, peripherally neuropathy)
- Symptomatic, untreated brain metastasis, leptomeningeal disease, or spinal cord compression. Patients are eligible if central nervous system (CNS) metastases are adequately treated and neurologically stable for at least 2 weeks prior to enrollment.
- Documented allergic or acute hypersensitivity reaction attributed to antibody treatments.
- Major surgical procedure other than for diagnosis within 28 days prior to 89Zr-DFO-REGN3767 injection or anticipation of need for a major surgical procedure during the course of the study.
For patients that will be treated with cemiplimab in combination with platinum containing chemotherapy, the following additional criteria apply:
- Age > 70 years
- Leucopenia <3 x 109/L
- Estimated glomerular filtration rate < 60 mL/min/1.73 m2
- Cardiovascular disease, such as New York Heart Association cardiac disease (Class II or greater), unstable angina, unstable cardiac arrhythmias, myocardial infarction < 3 months ago, or cerebrovascular accident < 6 months ago.
- Hearing loss
- Any other exclusion criteria, according to the local clinical practice guidelines for the chosen chemotherapy regimen.
History of autoimmune disease, including but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematous, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjögren's syndrome, Guillain-Barré syndrome, multiple sclerosis, vasculitis or glomerulonephritis.
- Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone may be eligible for his study.
- Patients with controlled type I diabetes mellitus on a stable dose of insulin regimen may be eligible for this study.
History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis.
• History of radiation pneumonitis in the radiation field (fibrosis) is permitted.
Treatment with systemic immunosuppressive medications (including but not limited to prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents) within 4 weeks prior to 89Zr-DFO-REGN3767 injection.
- Patients who have received acute, low-dose, systemic immunosuppressant medications (e.g. a one-time of dexamethasone for nausea) may be enrolled in the study after discussion with and approval by the sponsor.
- The use of inhaled corticosteroids for chronic obstructive pulmonary disease, mineralocorticoids (e.g. fludrocortisone) for patients with orthostatic hypotension, and low-dose supplemental corticosteroids for adrenocortical insufficiency are allowed.
- Prior allogeneic bone marrow transplantation or solid organ transplant.
Active infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C or tuberculosis infection; or diagnosis of immunodeficiency
- Patients will be tested for hepatitis C virus (HCV) and hepatitis B virus (HBV) at screening.
- Patients with known HIV infection who have controlled infection (undetectable viral load (HIV ribonucleic acid (RNA) polymerase chain reaction (PCR)) and CD4 count above 350 either spontaneously or on a stable antiviral regimen are permitted. For patients with controlled HIV infection, monitoring will be performed per local standards.
- Patients with hepatitis B who have a controlled infection (serum HBV deoxyribonucleic acid (DNA) PCR that is below the limit of detection AND receiving anti-viral therapy for hepatitis B) are permitted. Patients with controlled infections must undergo periodic monitoring of HBV DNA. Patients must remain on anti-viral therapy for at least 6 months beyond the last dose of investigational study drug.
- Patients who are HCV antibody positive who have controlled infection (undetectable HCV RNA by PCR either spontaneously or in response to a successful prior course of anti-HCV therapy) are permitted.
- Patients positive for HCV antibody are eligible only if PCR is negative for HCV RNA.
- Active infection, that requires systemic antibiotics within 2 weeks prior to 89Zr-DFO-REGN3767 injection.
- Any other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of 89Zr-DFO-REGN3767, or that may affect the interpretation of the results or render the patient at high risk from complications.
- Receipt of a live vaccine (including attenuated) within 30 days of planned start of study medication.
- Altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.
- Sponsor employee/member of the clinical site study team and/or his or her immediate family
- Women with a positive serum chorionic gonadotropin HCG pregnancy test at the screening/baseline visit. Breastfeeding women are also excluded.
- Women of childbearing potential* and sexually active men who are unwilling to practice highly effective contraception prior to the first dose of study therapy, during the study, and for at least 6 months after the last dose.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04706715
|Contact: E GE de Vries, MD, PhDfirstname.lastname@example.org|
|Contact: P P van de Donk, MDemail@example.com|
|University Medical Center Groninen||Recruiting|
|Groningen, Netherlands, 9713 GZ|
|Contact: E GE de Vries, MD, PhD +31503612934 firstname.lastname@example.org|
|Contact: P P van de Donk, MD +31503616161 email@example.com|
|Principal Investigator: E GE de Vries, MD, PhD|
|Principal Investigator:||E GE de Vries, MD, PhD||University Medical Center Groningen|
|Responsible Party:||Prof.dr. E.G.E. de Vries, Principal investigator, University Medical Center Groningen|
|Other Study ID Numbers:||
|First Posted:||January 13, 2021 Key Record Dates|
|Last Update Posted:||February 15, 2023|
|Last Verified:||February 2023|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||No|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
immune checkpoint inhibitor
positron emission tomography
Antineoplastic Agents, Immunological